2-(N-Boc-4-哌啶基)乙胺 | 146093-46-1

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-(N-Boc-4-哌啶基)乙胺
• 中文别名: 4-氨乙基-1-叔丁氧羰基哌啶；N-Boc-4-(2-氨基乙基)哌啶；2-(N-BOC-4-哌啶)乙胺
• 英文名称: 4-(2-aminoethyl)-1-piperidinecarboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-(2-aminoethyl)piperidine-1-carboxylate；4-(2-aminoethyl)-1-Boc-piperidine；4-(aminoethyl)-1-N-Boc-piperidine；1-(1,1-dimethylethoxycarbonyl)-4-(2-aminoethyl)piperidine
• CAS: 146093-46-1
• 化学式: C₁₂H₂₄N₂O₂
• mdl: MFCD04038459
• 分子量: 228.335
• InChiKey: LBQDLHPFISVBRU-UHFFFAOYSA-N

物化性质

• 沸点：
  316.0±15.0 °C(Predicted)
• 密度：
  1.010±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温和干燥环境

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 4-(2-Aminoethyl)-1-boc-piperidine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 4-(2-Aminoethyl)-1-boc-piperidine
CAS number: 146093-46-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H24N2O2
Molecular weight: 228.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-(N-Boc-4-哌啶基)乙胺 在 聚合甲醛 、 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 生成 4-[2-(甲基氨基)乙基]-1-哌啶羧酸 1,1-二甲基乙酯
  参考文献：
  名称：

  Autotaxin inhibitors

  摘要：

  本发明涉及一种新型化合物，它们是自体磷脂酶A抑制剂，以及它们的制备方法、含有它们的药物组合物和药物，以及它们在由自体磷脂酶A介导的疾病和紊乱中的应用。

  公开号：

  US20140171403A1
• 作为产物：
  描述：

  N-Boc-4-哌啶乙醇 在 palladium on activated charcoal 咪唑 、 sodium azide 、 氢气 、 碘 、 三苯基膦 作用下， 以 甲醇 、 二甲基亚砜 、 甲苯 为溶剂， 反应 32.5h， 生成 2-(N-Boc-4-哌啶基)乙胺
  参考文献：
  名称：

  非肽糖蛋白IIb / IIIa抑制剂。17.口服活性的，长效的非肽纤维蛋白原受体拮抗剂的设计和合成。

  摘要：

  据报道5（L-738，167），一种有效的，选择性的非肽纤维蛋白原受体拮抗剂的合成和药理学评估。化合物5抑制人凝胶过滤的血小板的聚集，IC50值为8 nM，发现抑制人内皮细胞与纤维蛋白原，纤连蛋白和玻连蛋白的附着力比抑制血小板的效果低> 33000倍聚合。在以100微克/ kg的剂量对狗口服5次后24小时，离体血小板聚集被抑制> 85％。5表现出的延长的药效学特性似乎是其与循环血小板上GPIIb / IIIa的高亲和力结合的结果，表明5适合一天一次给药。

  DOI：

  10.1021/jm9608117

文献信息

• [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2020264499A1

  公开（公告）日：2020-12-30

  The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.

  本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团（DIM）。DIM可以是DTM、一个连接酶结合基团（LBM）或赖氨酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂，并应用于IRAK介导的疾病。
• Chan–Evans–Lam Amination of Boronic Acid Pinacol (BPin) Esters: Overcoming the Aryl Amine Problem
  作者：Julien C. Vantourout、Robert P. Law、Albert Isidro-Llobet、Stephen J. Atkinson、Allan J. B. Watson

  DOI：10.1021/acs.joc.6b00466

  日期：2016.5.6

  The Chan–Evans–Lam reaction is a valuable C–N bond forming process. However, aryl boronic acid pinacol (BPin) ester reagents can be difficult coupling partners that often deliver low yields, in particular in reactions with aryl amines. Herein, we report effective reaction conditions for the Chan–Evans–Lam amination of aryl BPin with alkyl and aryl amines. A mixed MeCN/EtOH solvent system was found

  Chan–Evans–Lam反应是有价值的C–N键形成过程。但是，芳基硼酸频哪醇（BPin）酯试剂可能很难成为偶合剂，常常导致收率低，特别是在与芳基胺反应时。在此，我们报告了烷基-芳基胺与芳基BPin的Chan-Evans-Lam胺化反应的有效反应条件。发现混合的MeCN / EtOH溶剂系统可以使用芳基胺形成有效的C–N键，而烷基胺的偶联则不需要EtOH。
• TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20160376283A1

  公开（公告）日：2016-12-29

  The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

  本发明涉及式I化合物及其药用可接受的组合物，用作TBK/IKKε抑制剂。
• 异烟酰胺类AChE-GSK3双抑制剂及其制备方法与应用
  申请人：中国药科大学

  公开号：CN112047928B

  公开（公告）日：2022-09-23

  本发明公开了一种AChE/GSK‑3双抑制剂，包含如式(Ⅰ)所示的化合物或其药学上可接受的盐、溶剂化物，本发明所涉及的化学小分子能够有效的抑制GSK‑3β和AChE的酶活，并且可用于预防或治疗中枢神经系统疾病‑‑阿尔茨海默症。
• Discovery of 2-(cyclopropanecarboxamido)-N-(5-((1-(4-fluorobenzyl)piperidin-4-yl)methoxy)pyridin-3-yl)isonicotinamide as a potent dual AChE/GSK3β inhibitor for the treatment of Alzheimer's disease: Significantly increasing the level of acetylcholine in the brain without affecting that in intestine
  作者：Xueyang Jiang、Chang Liu、Manxing Zou、Huanfang Xie、Tailiang Lin、Weiping Lyu、Jian Xu、Yuan Li、Feng Feng、Haopeng Sun、Wenyuan Liu

  DOI：10.1016/j.ejmech.2021.113663

  日期：2021.11

  impairment-improvement effects. In this study, we characterized a new backbone of the AChE/GSK3β inhibitor 11c. It was identified as a highly potent AChE inhibitor and was found superior to donepezil, the first-line drug for the treatment of AD. In vivo studies confirmed that 11c significantly inhibited the activity of AChE in the brain but had little effect on the activity of AChE in the intestine. This advantage

  乙酰胆碱酯酶（AChE）抑制剂是目前 FDA 批准用于治疗阿尔茨海默病（AD）的一线药物。然而，较短的有效窗口限制了它们的治疗效果。临床研究证实，AChE 抑制剂和神经保护剂的组合表现出更好的抗 AD 作用。我们之前曾报道过双重 AChE/GSK3β（糖原合酶激酶 3β）调节剂具有神经保护作用和认知障碍改善作用。在这项研究中，我们表征了 AChE/GSK3β 抑制剂11c的新骨架。它被确定为一种高效的 AChE 抑制剂，并且优于多奈哌齐，后者是治疗 AD 的一线药物。体内研究证实，11c显着抑制脑内 AChE 的活性，但对肠内 AChE 的活性影响不大。预计11c 的这一优势将减少多奈哌齐引起的外周副作用。此外，生物标志物研究表明，11c还提高了大脑中乙酰胆碱和突触素的水平，并表现出神经保护作用。初步的体内和体外研究结果强调化合物的励磁潜在11C在AD的治疗。